Treatment with anti-TNF alpha does not induce reactivation of latent Salmonella enterica serovar Typhimurium infection in C3H/HeN mice.
Therapy with tumour necrosis factor-alpha (TNFalpha)-blocking agents is successful in treating inflammatory disorders, but carries an increased risk of manifest and reactivating infection with intracellular bacteria. In a mouse model of latent Salmonella typhimurium infection, neutralization of TNFalpha did not result in reactivation of infection, suggesting only a minor role for TNFalpha during latency of persistent Salmonella infection.
van Diepen
A
A
Department of Infectious Diseases, Leiden University Medical Center, RC Leiden, The Netherlands.
Martina
C A E
CA
Flierman
R
R
Janssen
R
R
van Dissel
J T
JT
D000818:Animals; D019138:Antibodies, Blocking / Q000008:administration & dosage; D002460:Cell Line; D000068800:Etanercept; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D008264:Macrophages / Q000276:immunology / Q000382:microbiology; D051379:Mice; D008809:Mice, Inbred C3H; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012481:Salmonella Infections, Animal / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D012486:Salmonella typhimurium / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology
D019138:Antibodies, Blocking; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept